Patent application number | Description | Published |
20130189661 | SCORING HUMOR REACTIONS TO DIGITAL MEDIA - As an individual or a group of individuals view various types of humor, a webcam, using video capture, collects mental state data from the individual or individuals. The webcam data is analyzed to determine physiological data, facial data, and actigraphy data. Further, the direct collection of physiological data—electrodermal activity, heart rate, heart rate variation, skin temperature, and respiration—from an individual or individuals complements the webcam data. Analysis of this mental state data allows for the accurate comprehension of individual humor preferences and allows the individual's humor preferences to be used by the system to recommend humorous material based on these preferences. | 07-25-2013 |
20130238394 | SALES PROJECTIONS BASED ON MENTAL STATES - Analysis of mental states is performed in order to project sales. Projections may be based on effectiveness of an advertisement, a product, or a service. Effectiveness may be based on various objectives including entertainment, education, awareness, persuasion, startling, and drive to action. Data, including facial information and physiological information, is captured for an individual viewer or group of viewers. In some embodiments, demographics information is also collected and used as a criterion for rendering the mental states of the viewers in a graphical format. In some embodiments, data captured from an individual viewer or group of viewers is used to optimize sales projections. | 09-12-2013 |
20130262182 | PREDICTING PURCHASE INTENT BASED ON AFFECT - Analysis of mental states is provided to evaluate purchase intent. Purchase intent may be determined based on viewing and sampling various products. Data is captured for viewers of a product where the data includes facial information, physiological data, and the like. Facial and physiological information may be gathered for a group of viewers. In some embodiments, demographics information is collected and used as a criterion for evaluating product or service purchase intent. In some embodiments, data captured from an individual viewer or group of viewers is used to optimize product purchase intent. | 10-03-2013 |
20150018707 | PAIN ANALYSIS USING ELECTRODERMAL ACTIVITY - A method for accurate pain analysis using a combination of electrodermal data and self-report information is described. To obtain pain measurements, electrodermal activity is collected and analyzed. One or more biosensors obtain electrodermal data from a person. The electrodermal data is filtered to produce skin conductance values. The skin conductance values are associated with self-report pain information from a person over multiple time regions. The associating allows electrodermal activity to be related to self-reported pain (SRP) data to derive an objective pain measurement. | 01-15-2015 |
Patent application number | Description | Published |
20130115582 | AFFECT BASED CONCEPT TESTING - Analysis of mental states pertaining to concept testing is described. Concepts may be evaluated by seeing a product, seeing a service, seeing a model, viewing an advertisement, and the like. Data which includes facial information is captured for viewers of a concept. Facial and physiological information is gathered for a group of viewers. Demographic information is collected and used as a criterion for evaluating the concept. Data captured from an individual viewer or group of viewers is used to optimize a concept. | 05-09-2013 |
20140051047 | SPORADIC COLLECTION OF MOBILE AFFECT DATA - A user may react to an interaction by exhibiting a mental state. A camera or other monitoring device can be used to capture one or more manifestations of the user's mental state, such as facial expressions, electrodermal activity, or movements. However, there may be conditions where the monitoring device is not able to detect the manifestation continually. Thus, various capabilities and implementations are described where the mental state data is collected on an intermittent basis, analyzed, and an output rendered based on the analysis of the mental state data. | 02-20-2014 |
20140058828 | OPTIMIZING MEDIA BASED ON MENTAL STATE ANALYSIS - Mental state data is collected from a group of people as they view a media presentation, such as an advertisement, a television show, or a movie. The mental state data is analyzed to produce mental state information, such as inferred mental states, facial expressions, or valence. The mental state information is used to automatically optimize the previously viewed media presentation. The optimization may change various aspects of the media presentation including the length of different portions of the media presentation, the overall length of the media presentation, character selection, music selection, advertisement placement, and brand reveal time. | 02-27-2014 |
20140112540 | COLLECTION OF AFFECT DATA FROM MULTIPLE MOBILE DEVICES - A user interacts with various pieces of technology to perform numerous tasks and activities. Reactions can be observed and mental states inferred from these performances. Multiple devices, including mobile devices, can observe and record or transmit a user's mental state data. The mental state data collected from the multiple devices can be used to analyze the mental states of the user. The mental state data can be in the form of facial expressions, electrodermal activity, movements, or other detectable manifestations. Multiple cameras on the multiple devices can be usefully employed to collect facial data. An output can be rendered based on an analysis of the mental state data. | 04-24-2014 |
Patent application number | Description | Published |
20120329711 | GLP-1 RECEPTOR AGONIST COMPOUNDS WITH A MODIFIED N-TERMINUS - The invention relates to GLP-1 receptor agonist compounds with a modified N-terminus. The compounds are of the formula Chem. 1: Y—Z—P, wherein P represents a fragment of a GLP-1 receptor agonist peptide lacking the two N-terminal amino acid residues; and Y—Z represents novel His-Ala mimetics. Examples of GLP-1 receptor agonist compounds are derived from human GLP-1 (7-37), exendin-4(1-39), or GLP-1 A (1-37). The invention also relates to derivatives of these compounds, in particular compounds with one or more albumin binding side chains capable of protracting the duration of action in vivo of these compounds. The peptides and derivatives of the invention have a good potency, a protracted pharmacokinetic profile, are stable against degradation by gastro intestinal enzymes, and/or have a high oral bioavailability. These properties are of importance in the development of GLP-1 receptor agonist compounds for subcutaneous, intravenous, and/or in particular oral administration. The invention also relates to intermediate products for use in the preparation of the GLP-1 receptor agonist compounds of the invention. | 12-27-2012 |
20130059781 | Long-Acting Gastrin Derivatives - The present invention relates to gastrin derivatives comprising gastrin or an analogue or fragment thereof and a derivatisation group and therapeutic use thereof. | 03-07-2013 |
20130288960 | Double-Acylated GLP-1 Derivatives - The invention relates to a derivative of a GLP-1 analogue, which analogue comprises a first K residue at a position corresponding to position 18 of GLP-1 (7-37) (SEQ ID NO: 1), a second K residue at another position, and a maximum of twelve amino acid changes as compared to GLP-1 (7-37); which derivative comprises two protracting moieties attached to said first and second K residue, respectively, via a linker, wherein the protracting moiety is selected from Chem. 1, Chem. 2, and Chem. 3: Chem.: HOOC—(CH | 10-31-2013 |
20140018290 | LEPTIN DERIVATIVES - The invention relates to Leptin derivatives, compositions and therapeutic use there-of. | 01-16-2014 |
Patent application number | Description | Published |
20100292133 | TRUNCATED GLP-1 DERIVATIES AND THEIR THERAPEUTICAL USE - The invention relates to truncated GLP-1 analogues, in particular a GLP-1 analogue which is a modified GLP-1(7-35) (SEQ ID No 1) having: i) a total of 2, 3, 4, 5 6, 7, 8, or 9 amino acid substitutions as compared to GLP-1(7-35), including a) a Glu residue at a position equivalent to position 22 of GLP-1(7-35), and b) an Arg residue at a position equivalent to position 26 of GLP-1(7-35); as well as derivatives thereof, and therapeutic uses and compositions. These analogues and derivatives are highly potent, have a good binding affinity to the GLP-1 receptor, also to the extracellular domain of the GLP-1 receptor, which is of potential relevance achieving long-acting, stable GLP-1 compounds with a potential for once weekly administration. | 11-18-2010 |
20110105720 | PROTEASE STABILIZED, ACYLATED INSULIN ANALOGUES - Novel acylated insulin analogues exhibiting resistance towards proteases can, effectively, be administered pulmonary or orally. The insulin analogues contain B25H and A14E or A14H. | 05-05-2011 |
Patent application number | Description | Published |
20100292133 | TRUNCATED GLP-1 DERIVATIES AND THEIR THERAPEUTICAL USE - The invention relates to truncated GLP-1 analogues, in particular a GLP-1 analogue which is a modified GLP-1(7-35) (SEQ ID No 1) having: i) a total of 2, 3, 4, 5 6, 7, 8, or 9 amino acid substitutions as compared to GLP-1(7-35), including a) a Glu residue at a position equivalent to position 22 of GLP-1(7-35), and b) an Arg residue at a position equivalent to position 26 of GLP-1(7-35); as well as derivatives thereof, and therapeutic uses and compositions. These analogues and derivatives are highly potent, have a good binding affinity to the GLP-1 receptor, also to the extracellular domain of the GLP-1 receptor, which is of potential relevance achieving long-acting, stable GLP-1 compounds with a potential for once weekly administration. | 11-18-2010 |
20110105720 | PROTEASE STABILIZED, ACYLATED INSULIN ANALOGUES - Novel acylated insulin analogues exhibiting resistance towards proteases can, effectively, be administered pulmonary or orally. The insulin analogues contain B25H and A14E or A14H. | 05-05-2011 |